Patent ID: 8252343
Filing Date: 2012-08-28
Classification: A61K,A61P

Abstract:
1. A method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis or reducing, inhibiting or treating allergy like symptoms in a subject suffering from allergy like symptoms, wherein the allergy-like symptoms are one or more selected from the group consisting of allergic rhinitis symptoms selected from the group consisting of nasal itching, sneezing, nasal congestion, rhinorrhea, postnasal drainage, throat itching, constant clearing of secretions from the throat, throat irritations, cough, ear itching, palate itching, headache, facial pressure, and facial pain, ocular symptoms selected from the group consisting of itching, swelling, increased lacrimation and redness, otic symptoms selected from the group consisting of decreased hearing, popping and fullness, and systemic symptoms selected from the group consisting of weakness, malaise, fatigue, poor appetite and cognitive impairment; asthma like symptoms selected from the group consisting of coughing, wheezing, shortness of breath, and chest tightness; atopic skin reactions and allergic skin reactions selected from the group consisting of scaly skin, itchy skin, inflamed skin, swollen skin and cracked skin; and gastrointestinal allergen related symptoms selected from the group consisting of general discomfort, gas and bloating, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising ClO 2 − , wherein administration of the therapeutically effective amount is effected not more than once every six months, once every year or once every two years.